Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Executive Summary
A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.
You may also be interested in...
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.